LeonaBio, a clinical-stage biopharmaceutical company, announced its participation in two major medical events in June 2026: the 5th Annual ALS Drug Development Summit and the BIO International Convention. The company will present on its ALS drug candidate ATH-1105, focusing on innovative trial designs and biomarker integration, and participate in a panel on future oncology trials. These presentations highlight LeonaBio's commitment to advancing treatments for diseases with high unmet needs, including ALS and metastatic breast cancer. The events provide a platform to showcase their progress and engage with the medical and investment communities.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
